CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 140 enrolled
Drug / intervention
EXPAREL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02713490
NCT02713490Phase 4Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty

Pacira Pharmaceuticals, Inc·interventional·Posted Mar 18, 2016·Updated Dec 11, 2020

In Brief

A Phase 4 clinical trial evaluating EXPAREL and Bupivacaine for Pain. Completed, enrolled 140 participants across 17 sites.

Detailed Summary

This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately 140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine HCl (10-15 mg).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 18, 2016
Enrollment StartApr 18, 2016
Primary CompletionFeb 8, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.3 years ago

Interventions

EXPARELdrug

EXPAREL and bupivacaine HCl

Bupivacainedrug

Single dose of bupivacaine HCl 0.5%